<DOC>
	<DOC>NCT00543387</DOC>
	<brief_summary>This study will investigate the safety, side effects and how well the body tolerates MK-5108 as well as determine different doses of MK-5108 in participants with advanced and/or refractory solid tumors.</brief_summary>
	<brief_title>Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001 AM4)</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Participant has a histologicallyconfirmed metastatic or locally advanced solid tumor that has failed to respond to standard therapy or progressed with standard therapy Participant has had chemotherapy, radiotherapy or biological therapy within 4 weeks prior to study start or has not recovered from adverse events caused by therapy more than 4 weeks earlier Participant is currently participating or has participated in a study with an investigational compound or device within 4 weeks prior to signing informed consent Participant has received more than 2 courses of chemotherapy for metastatic disease Participant has had prolonged neutropenia or neutropenia with fever from previous chemotherapy treatment Participant has a primary central nervous system tumor Participant is a regular or recreational user of any illicit drugs or has a recent history within the last year of drug or alcohol abuse Participant is pregnant, breastfeeding or planning to have children during the study Participant is Human Immunodeficiency Virus (HIV) positive Participant has a history of Hepatitis B or C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>